Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

NCT00910429 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00910429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00910429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
July 1, 2009
Completion date
August 19, 2019
Enrollment
237 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension